 |
|
|
| |
Clinical and virological characteristics of DAA-experienced patients with chronic
HCV infection treated with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX):
results from the Frankfurt Resistance Database
|
| |
| |
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Johannes Vermehren, Julia Dietz, Kai-Henrik Peiffer, Simone Susser, Stefan Zeuzem, Christoph Sarrazin
Medizinische Klinik 1, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany
|
| |
|
|
|
|
|
